{
    "clinical_study": {
        "@rank": "26840", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g", 
                "arm_group_type": "Experimental", 
                "description": "Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d"
            }, 
            {
                "arm_group_label": "Atorvastatin 20mg, Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of combination therapy of\n      omega-3-acids ethylesters 90/Atorvastatin calcium  in  type \u2161b hyperlipidemia"
        }, 
        "brief_title": "Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type \u2161b Hyperlipidemia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia, Familial Combined", 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hyperlipidemia, Familial Combined"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  LDL\u2265160mg/dl, 200mg/dl\u2264TG<500mg/dl\n\n          -  In the case of smokers, he agrees should be smoke-free\n\n          -  In the case of women of childbearing age, urine pregnancy test must be negative\n\n        Exclusion Criteria:\n\n          -  Patients with acute artery disease within 3 months\n\n          -  History of revascularization procedure or aneurism operation within 6months\n\n          -  Patients with myopathy, rhabdomyolysis\n\n          -  Patients with pancreatitis\n\n          -  Patients with HIV positive\n\n          -  History of malignant tumor within 2 years\n\n          -  Patients must be treated with medications prohibited for concomitant use during study\n             period\n\n          -  Patients with uncontrolled hypertension(SBP>180mmHg or DBP>110mmHg)\n\n          -  Serum Creatinine>1.2mg/dl(female), >1.4mg/dl(male)\n\n          -  AST or ALT > 2X ULN\n\n          -  CPK > 2X ULN\n\n          -  Patients with galactose intolerance or Lapp lactase deficiency, glucose-galactose\n             malabsorption\n\n          -  Allergy or Hypersensitive to investigational drug\n\n          -  History of drug or alcohol abuse within 2 years\n\n          -  In the case of smokers, who do not intend to non smoking\n\n          -  Women with pregnant, breast-feeding\n\n          -  Patients treated with any investigational drugs within 1 month at the time consents\n             are obtained\n\n          -  Not eligible to participate for the study at the discretion of investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035215", 
            "org_study_id": "13-OM-8302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g", 
                    "Atorvastatin 20mg, Placebo"
                ], 
                "intervention_name": "Atorvastatin 20mg", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor 20mg"
            }, 
            {
                "arm_group_label": "Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g", 
                "intervention_name": "Omega-3-acids ethylesters 90 4g", 
                "intervention_type": "Drug", 
                "other_name": "Omacor Soft Capsule 4g"
            }, 
            {
                "arm_group_label": "Atorvastatin 20mg, Placebo", 
                "intervention_name": "Placebo(Omega-3-acids ethylesters 90)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hyperlipidemia, Familial Combined", 
            "Omega 3 acids ethylesters 90", 
            "Atorvastatin"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anyang, Gyeonggi", 
                        "country": "Korea, Republic of", 
                        "zip": "431-070"
                    }, 
                    "name": "Hallym University Sacred Heart Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "405-760"
                    }, 
                    "name": "Gachon University Gil Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "152-703"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uijongbu, Gyeonggi", 
                        "country": "Korea, Republic of", 
                        "zip": "480-717"
                    }, 
                    "name": "Uijongbu St. Mary`s Hospital"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type \u2161b Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase \u2162 Study", 
        "overall_contact": {
            "email": "jmhong@kuhnil.com", 
            "last_name": "Kuhnil Clinical Research Team", 
            "phone": "+82-2-2175-9760"
        }, 
        "overall_official": [
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "Hong Seog Seo, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Uijongbu St. Mary`s Hospital", 
                "last_name": "Hee Kyoung Cheon, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hallym University Medical Center", 
                "last_name": "Sang-Ho Jo, Ph.d.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gachon University Gil Hospital", 
                "last_name": "Mi-Seung Shin, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The mean percent change of Triglyceride(TG)", 
            "safety_issue": "No", 
            "time_frame": "from baseline at week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035215"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The mean percent change of Triglyceride(TG)", 
                "safety_issue": "No", 
                "time_frame": "from baseline at week 4"
            }, 
            {
                "measure": "The mean percent change of Total Cholesterol(TC), LDL-C, HDL-C", 
                "safety_issue": "No", 
                "time_frame": "from baseline at week 4,8"
            }
        ], 
        "source": "Kuhnil Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kuhnil Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}